There is a lack of consensus regarding the treatment of inflammatory bowel disease after liver transplantation [LT],¹ although some LT patients have responded favourably and safely to biologic therapies such as anti-tumour necrosis factor [TNF] therapy and vedolizumab.^2–4 Recently tofacitinib, an oral small molecule Janus kinase [JAK] inhibitor, was shown to have potential efficacy as induction and maintenance therapy for moderately to severely active ulcerative colitis [UC].⁵ However, to our knowledge, there are no published data on the safety and efficacy of using tofacitinib in the management of active UC in LT recipients.

中文翻译：

---

托法替尼在肝移植患者溃疡性结肠炎中的应用

关于肝移植 [LT] 后炎症性肠病的治疗缺乏共识^1，尽管一些 LT 患者对生物疗法（如抗肿瘤坏死因子 [TNF] 治疗和维多珠单抗）的反应良好且安全。^2–4最近，托法替尼是一种口服小分子 Janus 激酶 [JAK] 抑制剂，已被证明具有作为中度至重度活动性溃疡性结肠炎 [UC] 诱导和维持治疗的潜在功效。⁵然而，据我们所知，尚无关于使用托法替尼治疗 LT 受者活动性 UC 的安全性和有效性的公开数据。